

NEWLINK GENETICS CORP
Form 8-K
March 05, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2019 (March 1, 2019)

NewLink Genetics Corporation
(Exact name of registrant as specified in its charter)

Delaware 001-35342 42-1491350
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

2503 South Loop Drive 50010
Ames, IA
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (515)
296-5555

Not applicable
(Former name or former address, if changed since last
report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act o

Section 5 - Corporate Governance and Management

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Executive Officer Equity Awards and Goals

Effective March 1, 2019, the Compensation Committee of the Board of Directors (the “Board”) of NewLink Genetics Corporation (the “Company”) approved 2019 base salary levels and target bonus levels, 2018 bonuses and stock awards for the named executive officers for the 2019 fiscal year.

Dr. Link’s base salary of \$593,910 remains the same. Dr. Vahanian’s base salary was reduced to \$475,000. Dr. Kennedy’s base salary was increased 3% to \$437,750. The 2019 target bonus levels for Dr. Link and Dr. Kennedy remain the same as 2018, while Dr. Vahanian’s 2019 target bonus level was reduced to 40%. Dr. Link and Dr. Vahanian were awarded bonuses for 2018 equal to 90% and 70%, respectively, of their previously-reported target bonus amounts for 2018. Dr. Kennedy was awarded a bonus equal to 100% of his previously-reported target bonus amount for 2018. Stock awards were approved as set forth on Exhibit 10.1.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
10.1	<u>2019 Equity Awards</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 5, 2019

NewLink Genetics Corporation

By: /s/ Carl W. Langren
Carl W. Langren
Its: Chief Financial Officer